Meeting the ambitious timelines for a COVID-19 vaccine will require an unprecedented multi-faceted, coordinated global response including governments, industry, academic researchers, delivery partners, donors and civil society. This graphic represents the pillars of this landscape — with those organizations mentioned by name representing just a small fraction of the growing number of contributors in the global response to the COVID-19 pandemic.
Excerpted from Five “P”s to Watch.
This graphic compares a conventional timeline for vaccine development, anticipating a COVID-19 vaccine available by May 2036, versus the accelerated goal of developing, producing and distributing a vaccine much, much faster. Excerpted from Five “P”s to Watch.
HIV vaccine research is making the search for a COVID-19 vaccine faster, safer and more inclusive. The global COVID-19 response evolves by the day—seemingly, even, by the minute—as the world has watched the tally of experimental diagnostics, therapeutics and vaccines tick up into the hundreds. If researchers achieve their goal of making the search for a COVID-19 vaccine the fastest vaccine development effort in history, much of that success will be due to the research knowledge, vaccine platforms, trial networks and community engagement models created through HIV vaccine research.
A snapshot of the COVID-19 vaccine pipeline. Excerpted from Five “P”s to Watch.
HIV represents one of the most challenging viruses ever encountered. Though an HIV vaccine has yet to be licensed, vaccine science has made enormous strides as it confronts this rapidly-mutating virus. Years of painstaking work to develop vaccines for HIV are now making possible the record-breaking timelines that researchers aspire to for the development of COVID-19 vaccines. Vaccines research has generated more scientific knowledge about immune function and responses than ever existed. And key vaccine platforms are fast-tracking the development and testing of experimental vaccines for COVID-19 today.
Excerpted from Five “P”s to Watch.
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.
In many ways, the collaborative research movement grew up around Vaccines. Thanks in large part to HIV advocacy, out-of date research models that were competitive and closed-door are increasingly yielding to more transparent and collaborative research and development efforts—in both the HIV and COVID-19 responses.
Building on big science partnerships, data sharing and collaboration pioneered over the last 15 years of Vaccines research and development, global initiatives are marshalling the talents, experiences and resources of key stakeholders. And just as HIV laid the foundation for more effective partnerships in research, lessons from the COVID-19 experience can also inspire greater collaboration and broader involvement by a range of players in the vaccines research effort.
Excerpted from 5 “P”s to Watch.
This brief provides information on mathematical modeling for the COVID-19 pandemic.
As the COVID-19 pandemic rages on across the world, the latest crisis is markedly reminiscent of the early days of HIV. And while the HIV epidemic is far from over, unrelenting activism, strong community engagement, partnerships and innovation are to thank for the strides the field has made towards controlling the epidemic.
Now, the response to COVID-19 is drawing heavily from these successes, and at the same time, forcing even more innovation on the HIV front.
In this episode of Px Pulse, we’ve compiled excerpts from two April webinars that offer unique perspectives on how COVID-19 and HIV are shaping one another. First, Mark Feinberg, CEO of IAVI, and Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI), speak to COVID-19 vaccine development, and the role of the Coalition for Epidemic Preparedness Innovation (CEPI) in spurring vaccine funding and collaboration. We then turn to community engagement experts Sinead Delany-Moretlwe, Director of Research at Wits RHI, Vincent Basajja of the Uganda Virus Research Institute, Jau Nanyondo from Uganda’s Makerere University Walter Reed Project and Philister Adhiambo from the Kenya Medical Research Institute, who explain how HIV prevention trials are adapting in the wake of COVID-19.